Information Provided By:
Fly News Breaks for November 26, 2019
Nov 26, 2019 | 07:57 EDT
Cowen analyst Charles Neivert lowered his price target on Dow Inc. to $50 from $57 citing the macro environment coupled with further deterioration of fundamentals. . The analyst said it proposes a highly challenging risk profile for ethylene dependent shares with a meaningful downside potential over the next six months. Neivert does see a substantive recovery in 2021. Neivert maintained his Market Perform rating on Dow Inc. shares.
News For DOW From the Last 2 Days
Dec 9, 2019 | 11:06 EDT
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA/MERRILL DOUBLE UPGRADES... To see the rest of the story go to See Story Here
Dec 9, 2019 | 10:20 EST
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qorvo (QRVO) and Skyworks (SWKS) double upgraded to Buy from Underperform at BofA/Merrill. 2. Fate Therapeutics (FATE) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jim Birchenough citing this weekend's update for the company's iPSC-derived NK-cell therapeutics pipeline, initial data for iPSC NKcell therapies FT500 and FT516, and updated comments on CD19 CAR-NK therapeutic FT596. 3. Wingstop (WING) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Katherine Fogertey saying while the shares are up over 30% over the past year, they have lagged the S&P 500 by over 30% since August 22 and now trade at a discount to peers. 4. Huntsman (HUN) and Fortive (FTV) upgraded to Buy from Neutral at Citi. 5. Dow Inc. (DOW) and Kraton (KRA) upgraded to Buy from Hold at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.